Melanotan I
Also known as: MT-I, MTI, NDP-MSH, NDP-α-MSH, [Nle4,D-Phe7]-α-MSH, [Nle4-D-Phe7]-alpha-MSH, afamelanotide (approved form), MELANOTAN
Synthetic melanocortin peptide; MC1R agonist; alpha-MSH analogue (linear)
What it is
Melanotan I is a peptide people use to stimulate skin tanning without sun exposure. Research has also explored it for photoprotection and sexual dysfunction. Not FDA-approved; a related compound (afamelanotide) is approved in Europe for a rare sun-sensitivity disorder; regulatory status of Melanotan I itself is unverified.
The scientific side
Melanotan I ([Nle4,D-Phe7]-α-MSH; NDP-MSH) is a superpotent, enzymatically resistant synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that binds to and activates the melanocortin 1 receptor (MC1R) with high affinity (binding IC50 ~1.2 nM; cAMP EC50 ~0.5 nM at hMC1R). Binding to MC1R stimulates adenylate cyclase, elevating intracellular cAMP, which drives melanogenesis and increases eumelanin content in skin (PMID 41489668, PMID 26293341). Unlike the endogenous α-MSH, Melanotan I incorporates norleucine at position 4 and D-phenylalanine at position 7, conferring superpotency and enzymatic stability (PMID 9760697, PMID 16412534). It also activates other melanocortin receptor subtypes (MC3R, MC4R, MC5R) to varying degrees (PMID 7980588, PMID 39296259). Additional reported biological activities include anti-inflammatory effects via modulation of cytokine and matrix metalloproteinase expression in human chondrocytes, modulation of feed intake and insulin action via central melanocortin pathways in animal models, and neuroprotective effects reported in preclinical models (PMID 36703981, PMID 38688422).
Class: Synthetic melanocortin peptide; MC1R agonist; alpha-MSH analogue (linear)
Administration & storage
- Administration
- Subcutaneous injection (PMID: 9113347PMID: 1658407PMID: 11045725PMID: 30142729PMID: 19224885PMID: 20545686)Intravenous injection (PMID: 9113347)Oral administration — no detectable plasma levels observed (PMID: 9113347)Intracerebroventricular infusion in animal studies (PMID: 38035762)Intraperitoneal injection in animal studies (PMID: 36703981PMID: 38688422)Transdermal — in vitro permeation through human skin demonstratednot validated clinically (PMID: 2155969)
- Storage
- No storage conditions for Melanotan I are specified in the reviewed abstracts. The HPLC analytical study assessed drug stability in biological matrices (cell culture media and human plasma) and the assay was described as 'stability-indicating,' but specific storage temperature or shelf-life data are not reported in the abstract.
- Cautions
- Unregulated Melanotan I sold online has unknown purity, preparation quality, and actual dose content — multiple national health organizations have issued safety warnings.,Case reports describe activation/changes in dysplastic nevi and newly emerging (dysplastic) nevi during or shortly after use; four cases of melanoma emerging from existing moles reported in association with melanotan use, though conclusive causal evidence is lacking (PMID: 28266027, PMID: 26315100).,Melanotan-associated transverse melanonychia (nail pigmentation change) has been reported as a case finding.,No detectable drug levels were observed following oral dosing, indicating this route is not effective for absorption; IV and SC routes were the only routes showing systemic absorption in pharmacokinetic studies.,The MHRA has raised awareness of the public health risk of blood-borne virus transmission from needle sharing among illicit users, and of potential product impurity.,Sterile technique is essential for any injected preparation; unverified internet-sourced peptides carry unknown contamination risks.
Legal & regulatory status
Not stated in reviewed literature as currently FDA-approved under the name Melanotan I. Abstract 59 notes NDP-α-MSH as a peptide agonist, and Abstract 55 refers to NDP-MSH as a tool compound. Abstract 1 states…
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Skin tanning / melanogenesis stimulation (sunless tanning) Human RCT
- Randomized, placebo-controlled, double-blind trial in 28 healthy white men. Ten subcutaneous injections of NDP-α-MSH over 12 days produced significant skin darkening in both poor- and good-tanning skin types (skin types I–IV); peak changes 1–3 weeks post-therapy. No darkening in placebo group. PMID 1658407 Levine N et al. JAMA. 1991.
- Seven volunteers (skin types III–IV) received 10 daily SC injections of MT-I at 0.16 mg/kg/day over 2 weeks. Tanning observed at face, neck, and forearm. Mean forearm eumelanin (PTCA) increased 98% from baseline one week post-treatment (P=0.003); eumelanin:pheomelanin ratio increased from 51:1 to 86:1. PMID 11045725 Dorr RT et al. Photochem Photobiol. 2000.
- Double-blind RCT in 77 Caucasian individuals. MELANOTAN (NDP-MSH) administration produced significant (p<0.001) increase in melanin density versus placebo, including in individuals with MC1R variant alleles (Val60Leu, Asp84Glu, Val92Met, Arg142His, Arg151Cys, Arg160Trp), who showed greater increases than those with no PMID 16293341 Fitzgerald LM et al. Peptides. 2006.
- Pharmacokinetic crossover trial (3 male volunteers, doses 0.08–0.21 mg/kg SC, 0.16 mg/kg IV, PO). SC dose completely bioavailable vs IV; no detectable levels after oral dosing. Significant tanning of forehead, arms, and neck after IV or SC dosing; tanning peaked 1 week post-drug but persisted 3 weeks after completion. PMID 9113347 Ugwu SO et al. Biopharm Drug Dispos. 1997.
- Photoprotection and skin cancer prevention Human observational
- Review noting that MT-I was patented and tested clinically for tanning; review authors suggest MT-I may provide a 'therapeutic tan with the potential to lower the risk of skin cancer,' though this is stated as a potential benefit under investigation. PMID 16412534 Hadley ME, Dorr RT. Peptides. 2006.
- Review noting regulated α-MSH analogue afamelanotide was undergoing phase II and III clinical trials for photoprotective potential in photosensitivity disorders and those prone to nonmelanoma skin cancer at time of publication. PMID 20545686 Langan EA et al. Br J Dermatol. 2010.
- Male and female sexual dysfunction (investigational) Human observational
- Review summarizing clinical development of MCR agonists (melanotan I, melanotan II, bremelanotide) for sexual arousal/orgasmic disorders in women and erectile dysfunction in men. Authors note data available warrants further investigation. PMID 25096243 Ückert S et al. Expert Opin Investig Drugs. 2014.
- Review noting MT-I was tested clinically for tanning; MT-II tested for diagnosis and treatment of male erectile dysfunction. PMID 16412534 Hadley ME, Dorr RT. Peptides. 2006.
- Central melanocortin system modulation of feed intake and metabolism (animal) Animal studies only
- Intracerebroventricular infusion of MTI at 0.03 nmol/h in sheep significantly reduced feed intake (P<0.0001). MTI increased plasma triiodothyronine and thyroxine (intake-independent), blunted insulin's inhibition of endogenous glucose production during hyperinsulinemic-euglycemic clamps (P<0.0001), and tended to reduce PMID 38035762 Ehrhardt RA et al. J Anim Sci. 2023.
- Neuroprotection / cognitive function (preclinical) Animal studies only
- Chronic NDP-α-MSH (340 μg/kg i.p., 50 days) in 5XFAD and 3xTg Alzheimer mouse models improved cognitive abilities at late-stage AD progression, decreased hyperphosphorylated Tau, and showed age-dependent effects on glial reactivity and p38 MAPK. PMID 36703981 Daini E et al. Front Immunol. 2022.
- Polysorbate 80-coated chitosan nanoparticles loaded with NDP-MSH, administered intraperitoneally in male Wistar rats, crossed the blood-brain barrier, accumulated in hippocampal CA1 neurons, and reversed decreased contextual fear memory expression in two neuroinflammation models (short-term and long-term HFD). PMID 38688422 Herrera G et al. Neuropharmacology. 2024.
- Anti-inflammatory effects in chondrocytes (in vitro) In vitro only
- In human osteoarthritic chondrocytes, α-MSH significantly reduced MMP-3 gene expression and secretion stimulated by IL-1β or TNF-α, increased TIMP-3 gene expression and release on resting cells, and reduced iNOS gene expression on cytokine-stimulated cells. Discrepancies noted between gene expression and protein releas PMID 26093672 Capsoni F et al. BMC Musculoskelet Disord. 2015.
- Peripheral nerve regeneration (preclinical, as NDP-MSH–loaded conduit) Animal studies only
- NDP-MSH loaded into self-assembling peptide hydrogel-functionalized biodegradable polyurethane nerve conduits; in rats with 10-mm sciatic nerve defects, the NDP-MSH conduit reduced apoptosis, promoted M2 immune microenvironment, and achieved structural, functional, and electrophysiological outcomes comparable to autogr PMID 41758331 Li J et al. J Mater Chem B. 2026.
- Lung preservation during ex vivo lung perfusion (preclinical) Animal studies only
- NDP-MSH administered to rats before lung procurement and during EVLP reduced inflammatory mediators, leukocyte release, and lactate production; improved vascular and airway parameters in cardiac death lungs; increased ATP content in ischemia/reperfusion lungs. MC1R and MC5R expression detected in native and ex vivo-per PMID 33865932 Lonati C et al. Peptides. 2021.
- Melanoma cell tyrosinase stimulation and growth inhibition (in vitro) In vitro only
- In 17 human melanoma cell lines, [Nle4,D-Phe7]α-MSH stimulated tyrosinase activity in one melanotic line (HD) and inhibited cell proliferation across both melanotic and amelanotic lines. Morphological differentiation (enlarged, dendritic cells) was observed. Prolonged residual inhibitory action on cell proliferation no PMID 8789740 Jiang J et al. Pigment Cell Res. 1995.
- Transdermal delivery / skin permeation research (in vitro/human tissue) In vitro only
- In vitro study demonstrated transdermal passage of (Nle4,D-Phe7)-α-MSH through human skin samples over 24 h at 36°C, confirmed by bioassay and radioimmunoassay. Regional differences in penetration noted; split-thickness skin allowed greater penetration, suggesting dermal binding. PMID 2155969 Dawson BV et al. J Invest Dermatol. 1990.
Safety signals
- Activation of dysplastic nevi and emergence of new (dysplastic) nevi during or shortly after use; four case reports of melanoma arising from existing moles in association with melanotan use (causal evidence not conclusive) PMID 28266027
- Melanotan I described as dangerous in relation to activation of dysplastic nevi PMID 26315100
- Melanotan-associated transverse melanonychia (nail pigmentation abnormality) PMID 22182016
- Eruptive pigmented lesion reported after melanotan injection PMID 21933235
- Unregulated melanotan I and II use associated with rhabdomyolysis, renal infarction, and priapism (systematic review finding) PMID 41890775
- Side effects in clinical pharmacokinetic study included occasional gastrointestinal upset and facial flushing PMID 9113347
- Illicit internet-sourced melanotan products carry risk of blood-borne virus transmission from needle sharing and risk from product impurity PMID 20545686
- Unregulated use associated with concerns about preparation quality, administration safety, and unknown dosage of illicitly obtained products PMID 28266027
- Rising use among younger people using tan-enhancing agents alongside sunbeds, with concerns about blood-borne infections PMID 40584950
Contraindications
- No formal contraindications are explicitly listed in the reviewed abstracts for Melanotan I specifically. The reviewed literature does note that unregulated use is associated with melanocytic changes and case reports of melanoma; patients with pre-existing dysplastic nevi or personal/family history of melanoma represent a population in which caution has been flagged by publications (though not stated as a formal contraindication). PMID 28266027
Protocol
500 mcg subcutaneous injection, daily. Cycle: 2-4 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Subcutaneous | 0.16 mg/kg/day | 10 daily injections over 2 weeks (Monday–Friday) | human | Research PMID 11045725 |
| Subcutaneous, intravenous, oral (oral: no detectable levels) | 0.08–0.21 mg/kg (SC); 0.16 mg/kg (IV and PO) | Five consecutive days per week for 2 weeks (ten doses) | human | Research PMID 9113347 |
| Not specified in abstract | Not stated numerically in abstract | Not stated in abstract | human | Research PMID 16293341 |
| Intracerebroventricular | 0.03 nmol/h (MTI, intracerebroventricular infusion) | Multi-day infusion (duration of individual experiments not fully specified in abstract) | animal | Research PMID 38035762 |
| Intraperitoneal | 340 μg/kg | 50 days | animal | Research PMID 36703981 |
| Systemic administration (route not fully specified in abstract) | Not stated numerically in abstract | Before lung procurement and during EVLP | animal | Research PMID 33865932 |
| Intraperitoneal (nanoparticle formulation) | Not stated numerically for NDP-MSH alone in abstract (administered via nanoparticle formulation, IP) | Not specified in abstract | animal | Research PMID 38688422 |
| subcutaneous injection | 500 mcg | daily · 2-4 weeks | fair-skinned adults seeking UV-independent tanning | [Community] |
| subcutaneous injection | 250 mcg | daily · 1-2 weeks | new users / first-time melanotan users, fair-skinned adults | [Community] |
| subcutaneous injection | 1000 mcg | daily · 2-4 weeks | experienced biohackers with darker baseline skin tone seeking accelerated tanning | [Community] |
| subcutaneous injection | 500 mcg | 2-3 times per week · ongoing / maintenance (weeks to months) | adults who have completed a loading phase and achieved desired tan | [Community] |
| subcutaneous injection | 100 mcg | daily · 1 week | very fair-skinned or sensitive individuals (Fitzpatrick type I-II) new to melanocortin peptides | [Community] |
| intranasal (nasal spray) | 500 mcg | daily · 2-4 weeks | adults who wish to avoid injections; tanning community | [Community] |
All studies (29)
- PMID 1658407 Human RCT
Skin tanning / melanogenesis stimulation (sunless tanning) - PMID 9113347 Human RCT
Skin tanning / melanogenesis stimulation (sunless tanning) - PMID 11045725 Human RCT
Skin tanning / melanogenesis stimulation (sunless tanning) - PMID 16293341 Human RCT
Skin tanning / melanogenesis stimulation (sunless tanning) - PMID 16412534 Human observational
Photoprotection and skin cancer prevention - PMID 20545686 Human observational
Photoprotection and skin cancer prevention - PMID 25096243 Human observational
Male and female sexual dysfunction (investigational) - PMID 2155969 In vitro only
Transdermal delivery / skin permeation research (in vitro/human tissue) - PMID 7980588
- PMID 8548013
- PMID 8789740 In vitro only
Melanoma cell tyrosinase stimulation and growth inhibition (in vitro) - PMID 9760697
- PMID 19224885
- PMID 21933235
Eruptive pigmented lesion reported after melanotan injection - PMID 22182016
Melanotan-associated transverse melanonychia (nail pigmentation abnormality) - PMID 26093672 In vitro only
Anti-inflammatory effects in chondrocytes (in vitro) - PMID 26293341
- PMID 26315100
Melanotan I described as dangerous in relation to activation of dysplastic nevi - PMID 28266027
Activation of dysplastic nevi and emergence of new (dysplastic) nevi during or shortly after use; four case reports of melanoma arising from existing moles in a - PMID 30142729
- PMID 33865932 Animal studies only
Lung preservation during ex vivo lung perfusion (preclinical) - PMID 36703981 Animal studies only
Neuroprotection / cognitive function (preclinical) - PMID 38035762 Animal studies only
Central melanocortin system modulation of feed intake and metabolism (animal) - PMID 38688422 Animal studies only
Neuroprotection / cognitive function (preclinical) - PMID 39296259
- PMID 40584950
Rising use among younger people using tan-enhancing agents alongside sunbeds, with concerns about blood-borne infections - PMID 41489668
- PMID 41758331 Animal studies only
Peripheral nerve regeneration (preclinical, as NDP-MSH–loaded conduit) - PMID 41890775
Unregulated melanotan I and II use associated with rhabdomyolysis, renal infarction, and priapism (systematic review finding)
Frequently asked
What is Melanotan I and how does it work?
Melanotan I (also called NDP-MSH or [Nle4,D-Phe7]-α-MSH) is a synthetic analogue of alpha-melanocyte stimulating hormone (α-MSH). It binds to the melanocortin 1 receptor (MC1R) on melanocytes with high affinity (binding IC50 ~1.2 nM; cAMP EC50 ~0.5 nM), stimulating adenylate cyclase and increasing cAMP, which drives melanin (eumelanin) production in the skin. It was designed to be superpotent and enzymatically resistant compared to natural α-MSH. It also activates other melanocortin receptor subtypes (MC3R, MC4R, MC5R).
Does Melanotan I actually cause tanning in humans?
Yes, clinical studies have demonstrated skin darkening. A randomized, placebo-controlled, double-blind trial in 28 healthy white men found significant skin darkening in treated subjects (skin types I–IV) but none in placebo subjects, peaking 1–3 weeks post-treatment. A separate study in 7 volunteers (skin types III–IV) found a mean 98% increase in forearm eumelanin content one week after a 2-week subcutaneous regimen at 0.16 mg/kg/day, with the eumelanin:pheomelanin ratio increasing from 51:1 to 86:1. A double-blind RCT in 77 Caucasians found significantly increased melanin density in treated vs. placebo subjects, including in those with MC1R variant alleles.
What dose of Melanotan I should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: human clinical studies used subcutaneous doses of 0.16 mg/kg/day given over 10 injections across 2 weeks, or doses of 0.08–0.21 mg/kg SC in a pharmacokinetic crossover study. These were controlled research settings with medical supervision. Unregulated self-administration carries serious risks including unknown product purity and melanocytic complications.
Is Melanotan I safe to use?
The safety profile of unregulated Melanotan I is a significant concern in the medical literature. Controlled clinical studies reported side effects including occasional gastrointestinal upset and facial flushing. However, the unregulated internet-sourced product has been associated with activation of dysplastic nevi, newly emerging nevi, and four case reports of melanoma arising from existing moles during or shortly after use (causal evidence not conclusive). Systematic review also identified associations with rhabdomyolysis, renal infarction, and priapism. Risks of needle sharing (blood-borne virus transmission) and product impurity have been flagged by health authorities. Multiple national health organizations have issued safety warnings.
Can I take Melanotan I orally instead of injecting it?
Published pharmacokinetic research found no detectable drug levels in plasma following oral dosing at 0.16 mg/kg in human volunteers — only subcutaneous and intravenous routes produced measurable systemic exposure and tanning effects. Oral administration does not appear to be an effective route for this peptide based on available evidence.
Is Melanotan I the same as afamelanotide?
Melanotan I and afamelanotide share the same chemical structure ([Nle4,D-Phe7]-α-MSH / NDP-MSH). The term 'afamelanotide' is the approved International Nonproprietary Name used for the regulated pharmaceutical form that has undergone formal clinical testing and received approval for specific medical indications (e.g., in Germany, per PMID 41489668). 'Melanotan I' typically refers to the unregulated, illicitly sold form. The reviewed literature emphasizes that afamelanotide has been thoroughly tested, while illegal melanotans carry additional risks due to unknown preparation, purity, and dosage.
What happens if I combine Melanotan I with other tanning methods or compounds?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Melanotan I produced tanning in human studies without UV exposure (PMID 1658407, PMID 11045725). Users of unregulated tan-enhancing agents (including melanotan I/II) have been observed to also use sunbeds more frequently, which may compound UV-related health risks. No controlled studies combining Melanotan I with other compounds are described in the reviewed abstracts.
Where can I buy Melanotan I?
I don't recommend vendors or sources. Please consult a licensed provider. Note: reviewed literature describes Melanotan I as purchasable illicitly online, but unregulated products carry unknown purity and safety risks, and multiple national health organizations have issued warnings about their use.
Can Melanotan I affect moles or skin lesions?
Yes — this is a documented safety concern. Published case reports and reviews report activation of dysplastic nevi, emergence of new (dysplastic) nevi, and four cases of melanoma arising from existing moles during or shortly after melanotan use. While conclusive causal evidence is lacking, the dermatology literature emphasizes awareness of this association and has described melanotan use as dangerous in patients with pre-existing dysplastic nevi (PMID 28266027, PMID 26315100, PMID 21933235). Please speak with a licensed healthcare provider if you have any pigmented lesions.
Has Melanotan I been studied for anything other than tanning?
Yes. Published research has explored several other uses, predominantly in preclinical (animal and cell) settings. These include: sexual dysfunction treatment (reviewed alongside melanotan II and bremelanotide, PMID 25096243); central regulation of feed intake and metabolism in sheep; neuroprotection and cognitive improvement in Alzheimer mouse models; anti-inflammatory effects in human chondrocytes in vitro; peripheral nerve regeneration via NDP-MSH–loaded conduits in rats; and lung preservation during ex vivo lung perfusion in rats. Human evidence outside of tanning remains limited.